Core Insights - Oculis Holding AG has completed enrollment in Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 eye drops targeting diabetic macular edema (DME), with over 800 patients enrolled across 119 sites [1][2][7] - Topline data from these trials is expected in Q2 2026, followed by a New Drug Application (NDA) submission to the FDA [2][4][10] - If approved, OCS-01 will be the first topical eye drop treatment for DME, addressing significant unmet medical needs [3][6] Company Overview - Oculis is a global biopharmaceutical company focused on innovative treatments for ophthalmic and neuro-ophthalmic diseases [1][11] - The company is developing OCS-01 as a non-invasive alternative to current invasive treatments for DME, which typically require injections [6][11] - Oculis' proprietary OPTIREACH technology enhances drug delivery to the retina, improving treatment accessibility [6][11] Industry Context - DME is a leading cause of visual loss and legal blindness among diabetic patients, currently affecting approximately 37 million people globally, with projections of 53 million by 2040 [9] - There is a critical need for effective and less burdensome treatments for DME, as existing therapies often involve invasive procedures [9][10]

Core Viewpoint - Oculis Holding AG has completed enrollment in Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 eye drops aimed at treating diabetic macular edema (DME), with pivotal data expected in Q2 2026, potentially leading to the first non-invasive topical treatment for DME [1][2][3] Company Overview - Oculis is a global biopharmaceutical company focused on innovative treatments for ophthalmic and neuro-ophthalmic diseases, with a pipeline that includes OCS-01 for DME, OCS-05 for acute optic neuritis, and OCS-02 for dry eye disease [12] Clinical Trials - The DIAMOND program consists of two Phase 3, double-masked, randomized trials evaluating the efficacy and safety of OCS-01 in over 800 patients, with a primary endpoint of change in best corrected visual acuity after 52 weeks [11][8] - Topline data from both trials is anticipated in the second quarter of 2026, followed by a New Drug Application (NDA) submission to the FDA [2][8] Product Details - OCS-01 is an OPTIREACH® formulation of high concentration dexamethasone eye drops, designed to provide a non-invasive treatment option for DME, contrasting with current invasive methods like intravitreal injections [7][9] - The product aims to improve drug solubility and increase residence time on the eye surface, facilitating treatment access in early disease stages [9] Market Need - DME is a leading cause of visual loss in diabetes, currently affecting approximately 37 million people globally, with projections to rise to 53 million by 2040, highlighting the urgent need for effective and less burdensome treatments [10]

Core Insights - Oculis Holding AG will host an R&D Day on April 15, 2025, to provide updates on its clinical candidates and future development strategies [1][2][3] Company Overview - Oculis is a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases, with a pipeline that includes OCS-01 for diabetic macular edema (DME), Licaminlimab for dry eye disease (DED), and Privosegtor for acute optic neuritis [16] Clinical Development Updates - The R&D Day will feature updates on the Phase 3 DIAMOND trials for OCS-01 eye drops in DME, the development plan for Licaminlimab in DED, and expanded data from the ACUITY Phase 2 trial for Privosegtor [2][3] - OCS-01 is a high concentration dexamethasone eye drop aimed at providing a non-invasive treatment for DME, addressing limitations of current invasive treatments [4][5] - Licaminlimab is an anti-TNFα eye drop candidate showing positive effects in Phase 2 trials for DED, with a genetic biomarker identified for improved response [9][10] - Privosegtor has shown neuroprotective benefits in acute optic neuritis, with orphan drug designation from both the FDA and EMA [13][14] Market Need and Impact - DME affects approximately 37 million people globally, with projections to rise to 53 million by 2040, highlighting the urgent need for effective treatments [6][8] - DED impacts over 110 million people in G7 countries, with a significant unmet need as 87% of chronic patients remain unsatisfied with current treatments [11][12] - Acute optic neuritis affects up to 8 in 100,000 people and currently lacks specific neuroprotective therapies, indicating a substantial market opportunity for Privosegtor [15]

Core Insights - Oculis Holding AG will host an R&D Day on April 15, 2025, to provide updates on its clinical candidates and business strategy [1][2][3] Company Overview - Oculis is a global biopharmaceutical company focused on ophthalmic and neuro-ophthalmic diseases, with a pipeline that includes OCS-01 for diabetic macular edema (DME), Licaminlimab for dry eye disease (DED), and Privosegtor for acute optic neuritis [16] Clinical Development Updates - The R&D Day will feature updates on the Phase 3 DIAMOND trials for OCS-01, the development plan for Licaminlimab in DED, and the expanded data analysis from the ACUITY Phase 2 trial for Privosegtor [2][3] - OCS-01 is a high concentration dexamethasone eye drop aimed at providing a non-invasive treatment for DME, which currently affects approximately 37 million people globally and is expected to rise to 53 million by 2040 [4][6][8] - Licaminlimab is an anti-TNFα eye drop candidate that has shown positive effects in Phase 2 trials for DED, which impacts over 110 million people in G7 countries [9][11][12] - Privosegtor has demonstrated neuroprotective benefits in acute optic neuritis, a condition affecting up to 8 in 100,000 people worldwide, and has received orphan drug designation from both the FDA and EMA [13][15] Market Need - There is a significant unmet need for effective treatments for DME and DED, as current therapies often require invasive methods or do not adequately address patient needs [8][12]

Core Viewpoint - Oculis Holding AG reported significant clinical advancements and financial results for the year 2024, highlighting its commitment to developing innovative treatments for ophthalmic and neuro-ophthalmic diseases, with a strong focus on executing its late-stage clinical portfolio in 2025 [2][6][18] Clinical Highlights and Upcoming Milestones - The company achieved positive Phase 2 topline results from the ACUITY trial for Privosegtor (OCS-05) in acute optic neuritis and the RELIEF trial for Licaminlimab (OCS-02) in dry eye disease [2][6] - Enrollment for the Phase 3 DIAMOND trials of OCS-01 in diabetic macular edema (DME) is on track to be completed in the coming months, with top-line data expected in the first half of 2026 [7] - A $100 million equity financing was successfully completed to support the advancement of the clinical portfolio [6][8] Financial Highlights - As of December 31, 2024, the company had total cash, cash equivalents, and short-term investments of CHF 98.7 million or $109.0 million, an increase from CHF 91.7 million or $108.9 million at the end of 2023 [5][8] - The net loss for Q4 2024 was CHF 28.7 million or $32.6 million, compared to CHF 12.5 million or $14.1 million for the same period in 2023 [10][14] - For the full year 2024, the net loss was CHF 85.8 million or $97.4 million, a slight decrease from CHF 88.8 million or $98.8 million in 2023 [10][14] Research and Development Expenses - Research and development expenses for Q4 2024 were CHF 11.8 million or $13.4 million, up from CHF 8.0 million or $9.0 million in Q4 2023 [10][14] - For the full year 2024, research and development expenses totaled CHF 52.1 million or $59.1 million, compared to CHF 29.2 million or $32.6 million in 2023 [10][14] Future Outlook - The company plans to provide further updates on its business and pipeline development during the R&D Day scheduled for April 15, 2025, in New York City [4][6]

Group 1 - Ovid Therapeutics reported a quarterly loss of $0.13 per share, better than the Zacks Consensus Estimate of a loss of $0.16, and an improvement from a loss of $0.22 per share a year ago, resulting in an earnings surprise of 18.75% [1] - The company posted revenues of $0.08 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 45.71%, compared to year-ago revenues of $0.14 million [2] - Ovid Therapeutics shares have declined approximately 47.6% since the beginning of the year, contrasting with the S&P 500's decline of 4.5% [3] Group 2 - The earnings outlook for Ovid Therapeutics is mixed, with the current consensus EPS estimate for the coming quarter at -$0.15 on revenues of $0.15 million, and -$0.64 on revenues of $0.55 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which Ovid Therapeutics belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Core Insights - Oculis Holding AG is a global biopharmaceutical company focused on saving sight and improving eye care [3] - The company will present at the Leerink Global Healthcare Conference on March 11, 2025, at 3:00 PM ET [1] - Oculis has a differentiated pipeline including innovative product candidates such as OCS-01, OCS-05, and OCS-02 [3] Company Overview - Oculis is headquartered in Switzerland and has operations in the U.S. and Iceland [3] - The management team has a successful track record and is supported by leading international healthcare investors [3] Upcoming Events - The company will be available for one-on-one meetings during the conference, and interested investors can contact their representatives [1] - A live webcast of the fireside chat will be accessible on the Oculis website [2]